Maxim Group Reiterates $135.00 Price Target for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on GWPH. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a buy rating to a hold rating in a research note on Monday, July 24th. BidaskClub raised GW Pharmaceuticals PLC from a strong sell rating to a sell rating in a research note on Wednesday, June 14th. TheStreet downgraded GW Pharmaceuticals PLC from a c- rating to a d+ rating in a research note on Wednesday, May 10th. ValuEngine raised GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Wednesday, June 21st. Finally, Cantor Fitzgerald reissued a buy rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $147.94.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 100.52 on Monday. The firm has a 50-day moving average price of $107.59 and a 200 day moving average price of $113.61. The firm’s market cap is $2.54 billion. GW Pharmaceuticals PLC has a 12-month low of $79.62 and a 12-month high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The firm had revenue of $3.14 million during the quarter, compared to the consensus estimate of $2.10 million. During the same period in the prior year, the firm posted ($0.05) EPS. On average, equities research analysts anticipate that GW Pharmaceuticals PLC will post ($5.28) earnings per share for the current fiscal year.

WARNING: This piece was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/08/10/maxim-group-reiterates-135-00-price-target-for-gw-pharmaceuticals-plc-nasdaqgwph.html.

Several institutional investors have recently modified their holdings of GWPH. Creative Planning boosted its position in shares of GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,603 shares during the last quarter. Bank of Montreal Can boosted its position in shares of GW Pharmaceuticals PLC by 2,419.0% in the first quarter. Bank of Montreal Can now owns 2,519 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 2,419 shares during the last quarter. Rothschild Investment Corp IL boosted its position in shares of GW Pharmaceuticals PLC by 2.7% in the first quarter. Rothschild Investment Corp IL now owns 10,437 shares of the biopharmaceutical company’s stock worth $1,262,000 after buying an additional 272 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of GW Pharmaceuticals PLC by 21.4% in the first quarter. Candriam Luxembourg S.C.A. now owns 17,000 shares of the biopharmaceutical company’s stock worth $2,056,000 after buying an additional 3,000 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of GW Pharmaceuticals PLC during the first quarter worth about $520,000. Institutional investors and hedge funds own 75.77% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply